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Abstract
Ichthyosis with confetti (IWC) is an autosomal dominant congenital ichthyosis also known as ichthyosis variegata or
congenital reticular ichthyosiform erythroderma. It manifests at birth with generalized ichthyosiform erythroderma
or with a collodion baby picture. The erythrodermic and ichthyotic phenotype persists during life and its severity
may modify. However, the hallmark of the disease is the appearance, in childhood or later in life, of healthy skin
confetti-like spots, which increase in number and size with time. IWC is a very rare genodermatosis, with a prevalence
<1/1,000,000 and only 40 cases reported worldwide. The most important associated clinical features include ear
deformities, mammillae hypoplasia, palmoplantar keratoderma, hypertrichosis and ectropion. IWC is due to dominant
negative mutations in the KRT10 and KRT1 genes, encoding for keratins 10 and keratin 1, respectively. In this context,
healthy skin confetti-like spots represent “repaired” skin due to independent events of reversion of keratin gene mutations
via mitotic recombination. In most cases, IWC clinical suspicion is delayed until the detection of white skin spots. Clinical
features, which may represent hint to the diagnosis of IWC even before appearance of confetti-like spots, include ear and
mammillae hypoplasia, the progressive development of hypertrichosis and, in some patients, of adherent verrucous
plaques of hyperkeratosis. Altogether the histopathological finding of keratinocyte vacuolization and the nuclear staining
for keratin 10 and keratin 1 by immunofluorescence are pathognomonic. Nevertheless, mutational analysis of KRT10 or
KRT1 genes is at present the gold standard to confirm the diagnosis. IWC has to be differentiated mainly from congenital
ichthyosiform erythroderma. Differential diagnosis also includes syndromic ichthyoses, in particular Netherton syndrome,
and the keratinopathic ichthyoses. Most of reported IWC cases are sporadic, but familial cases with autosomal dominant
mode of inheritance have been also described. Therefore, knowledge of the mutation is the only way to properly counsel
the couples. No specific and satisfactory therapy is currently available for IWC. Like for other congenital ichthyoses, topical
treatments (mainly emollients and keratolytics) are symptomatic and offer only temporary relief. Among systemic
treatments, retinoids, in particular acitretin, improve disease symptoms in most patients. Although at present there is
no curative therapy for ichthyoses, treatments have improved considerably over the years and the best therapy for
each patient is always the result of both physician and patient efforts.
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Ichthyosis with confetti (IWC) [1] is an autosomal
dominant congenital ichthyosis also known as ichthyosis
variegata [2] or congenital reticular ichthyosiform erythro-
derma (CRIE) [3], the latter being the disease name
recommended in the clinical-genetic classification of
inherited ichthyoses, developed by the First Ichthyosis
Consensus Conference in 2009 [4]. According to the
current classification, IWC belongs to non-syndromic
ichthyoses [4]. IWC manifests at birth with generalized
ichthyosiform erythroderma [1, 3, 5–16] or with a
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collodion baby picture [17–19]. The hallmark of this form
of ichthyosis is the appearance, in childhood or later in life,
of confetti-like spots of pale and normal-appearing skin,
which increase in number and size with time [1, 3, 5–19].
Methods
A literature search was performed on PubMed from 1984,
when IWC was first described, to April 30, 2015. In
addition, the Orphanet database [20] was looked at. The
following search terms were used: “ichthyosis with confetti”,
“congenital reticular ichthyosiform erythroderma”, “ichthy-
osis variegata”, “MAUIE syndrome”. We then checked the
bibliography of each article to identify additional references.
Altogether, 17 reports containing a total of 40 IWC cases
were identified.
Epidemiology
IWC is a very rare genodermatosis, with a prevalence <1/
1,000,000 [20]. To our knowledge, only 40 IWC cases have
been reported (Table 1) [1, 3, 5–19]. The disease may be
underdiagnosed as 9 cases have been described between
1984 and 2010 [1, 3, 5, 7, 8, 10–12], while ten cases have
been collected by Choate et al. who deciphered the causa-
tive gene in 2010 [13] and 21 additional cases have been re-
ported since then [15–17, 19].
Clinical description
IWC manifests at birth as a non-bullous generalized
ichthyosiform erythroderma [1, 3, 10–12, 16, 19] or as a
collodion baby [17–19]. The collodion membrane is typic-
ally shed within the first days of life [17–19]. The
erythrodermic and ichthyotic phenotype (Fig. 1a–d) persists
during life, even if its severity may modify [19]. In addition,
the extent and type of scaling and hyperkeratosis vary sig-
nificantly, ranging from white fine scales [11, 12], highly
reminiscent of congenital ichthyosiform erythroderma, to
verrucous hyperkeratotic adherent plaques more evident
on the limbs [17] (Fig. 1a–c). Of note, with time patients
develop confetti-like spots of healthy skin (Fig. 1d–e) on
the erythrodermic background. These are the hallmark of
the disease and frequently suggest the correct diagnosis.
Spots start appearing during childhood, gradually increase
in number to hundreds [13] and enlarge from 2 to 10 mm
up to 4 cm in diameter [1, 11, 13, 14, 17]. Sometimes, they
are recognized only after hyperkeratosis shedding due to
retinoid therapy [1, 3, 5, 11, 12, 17]. The spots are regularly
present on the trunk [6, 17, 18] and may spread to limbs
and the rest of the body. Healthy spots seem to follow a dis-
tribution gradient across the skin, being largest and more
numerous on the neck, décolleté and scapula regions, fewer
and smaller on arms and legs, and rare on the face [19].
Moreover, they have been described either as depressed [1,
11] or slightly elevated [6] with respect to the surrounding
skin. Due to the presence of many, at instance confluent,
confetti-like spots, the adjacent ichthyotic skin may assume
a reticulate pattern [3, 6, 12]. Of note, a later age at first ap-
pearance of confetti-like spots (22 years), a smaller size
(maximum 4 mm) and a predominant involvement of flex-
ures characterize the recently described IWC-II subtype
[16].
Table 1 summarizes all the clinical features, when
described, in previously reported IWC patients. Ectoder-
mal malformations, specifically ear deformities (Fig. 1e–f )
and mammillae hypoplasia (Figs. 1d and 2a) are typical of
IWC patients [17–19]. Ear deformities, comprising micro-
pinna (small ears and external auditory canal) and, in a
more general way, ear hypoplasia, are already evident at
birth [18]. Mammillae hypoplasia has been only reported
by Spoerri et al. [19]. However, it can be underestimated
as Spoerri noticed that it seems visible on previous pub-
lished pictures of some IWC patients [3, 12] and a reeval-
uation of our two patients [17] confirmed its presence
(Figs. 1d and 2a).
Palmoplantar keratoderma (PPK) is associated with
most IWC cases (Fig. 2b) [3, 5, 6, 10–12, 14, 17–19]. It
may be characterized by an orange-red color [6, 12],
increased palmar skin marks [6, 12, 18] and absent finger
dermatoglyphs [14]. Disproportionately severe PPK com-
pared with body hyperkeratosis has been reported in the
IWC-II subtype [16].
Hyperpigmented, irregular-shaped macules on the ery-
throkeratotic skin have been reported in a few cases [3, 9].
More frequently, hyperpigmentation within healthy skin
spots has been described [19].
Hypohidrosis with temperature intolerance [18] and
pruritus [6, 12, 17, 19] are likely due to the ichthyosiform
skin condition.
Hypertrichosis is a frequent and characteristic IWC sign
[10, 11, 14, 17, 19]. It can be apparent already in early
childhood, and is preferentially localized to dorsal acral
areas (Fig. 2c) [17, 19], with long hair even on the back of
hands and fingers [14], but can be generalized (Fig. 2d)
[17]. Hypertrichosis is confined to areas of ichthyotic skin
[19] and never present in confetti-like spots [14]. Scaling
usually also involves the scalp (Fig. 2e) [17, 19], sometimes
causing alopecia [19]. IWC patients may show reduced
eyebrows and eyelashes [19] and diffuse hair loss [11].
Scalp hair heterochromia has been reported [14].
Nails may appear thickened [18], with elongated nail
plates and enlarged lunulae (Fig. 2f) [19]. Subungual hyper-
keratosis may induce nail curving (Fig. 2g) [3, 18, 19], the
so called “unguis inflexus” [19].
Other frequent manifestations of IWC are eclabion
(outward lip eversion) and ectropion (out turning of the
eyelids) (Fig. 2h) [6, 11, 14, 17–19]. Additional but rarely
reported signs of eye involvement are strabismus and
nystagmus [19].
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Table 1 Clinical findings in 40 reported cases of ichthyosis with confetti






S/HK EM MH PPK DAH EE Additional findings Molecular analysis
a1 [1] 14 M −/+ +/8 +/NR NR NR NR NR NR SS NP
2 [3] 57 F −/+ +/NR +/+ NR f+ + NR NR HES, LNP, UI NP
b3 [7] 17 M −/+ +/since birth +/NR + NR - - + AU, E, NMSC NP
b4 [8] 30 F −/+ +/NR +/NR + NR - - + AU, NMSC NP
5 [10] 8 F −/+ +/years after +/NR NR NR + + NR NR NP
6 [11] 8 F −/+ +/6 +/NR NR NR + + + DHL, P NP
7 [12] 32 M −/+ +/10 +/+ NR f+ + NR NR P NP
c8 [17] 3 F +/+ +/2.5 +/+ + c+ + + + GA, GH, JCF, cLL/LNP, P,
PR, SI, SS/LW, cUI
KRT10: c.1383_1414del32
(exon 7), de novo
c9 [17] 6 M +/+ +/5 +/+ + c+ + + + GA, JCF, cLNP, P, cSI,
SS/LW, cUI
KRT10: c.1374-1G > C
(intron 6), de novo
10–29
[13, 15, 18]
18, 42, g11, NR:17 g1F, 4 F 5 M
NR:10






NR NR hGA:8, gJCF, hNMSC:3,
hPH:4, gUI
KRT10:




c.1374-1G > A (intron 6),
de novo
c.1373 + 1G > A (intron 6)








30 [19] Child F +/+ +/7 +/NR + + + + + LL/LNP, P, REE, SI, SS/LW,
UI
KRT10: c.1374-1G > A
(intron 6), de novo
31 [19] Young adult M +/+ +/12-13 +/NR + + - + + HHSS, LL/LNP, N, REE, S,
SI, SS/LW
KRT10: c.1374-1G > C
(intron 6), de novo
32 [1, 6, 9, 19] 12 F −/+ +/10 +/+ + + + + + DFL, HES/HHSS, JCF,
LL/LNP, P, S, SS/LW, UI
KRT10: c.1506_1507delAA,
(exon 7), de novo
33 [5, 14, 19] 5 F −/+ +/8 +/NR + + + + + DFL, HHSS, JCF, LL/LNP, N,
P, REE, S, SS/LW, UI
KRT10: c.1546_1551delinsT
(exon 7), de novo
34 [19] Child F +/+ +/7 +/NR + + + + - SS/LW KRT10: c.1557_1558delCG















Table 1 Clinical findings in 40 reported cases of ichthyosis with confetti (Continued)
35 [19] Young adult F +/+ +/12-14 +/NR NI + + + - DFL, HHSS, LL/LNP,
SS/LW, UI
KRT10: c.1573_1574dupA
(exon 7), de novo
d36 [19] Young adult F NR NR NR NR NR NR NR NR NR KRT10: c.1573_1574dupA
(exon 7), de novo
37 [16] 35 M −/+ +/22 NR NR NR + NR NR NR KRT1: c.1886insG (exon 9),
de novo
e38–40 [16] 3 to 9 M −/+ - NR NR NR + NR NR NR KRT1: c.1886insG (exon 9)
Most reported clinical findings: CB/CIE colloidon baby/congenital ichthyosiform erythroderma; HSS healthy skin spots; S/HK scaling/hyperkeratosis; EM ear malformation; MH mammillae hypoplasia; PPK palmoplantar
keratoderma; DAH dorsal acral hypertrichosis; EE eyelid ectropion; + present; − absent
Additional findings: AU alopecia universalis; DFL decreased finger length (relative to palm). DHL diffuse hair loss; E eclabion; GA gait abnormality due to joint contractions of the limbs; GH generalized hypertrichosis;
HES hyperpigmentation on erythrokeratotic skin; HHSS hyperpigmentation in healthy skin spots; JCF joint contractions of the fingers; LL/LNP large lunulae/ long nail plates; N nystagmus; NMSC nonmelanoma skin
cancer; P pruritus. PH peripheral hyperreflexia; PR psychomotor retardation; REE reduced eyebrows and eyelashes; S strabismus; SI scalp involvement; SS/LW short stature/ low weight (relative to age); UI unguis inflexus;
NR not reported. NP not performed
aCamenzind et al. [1] reported a second IWC patient (patient 32 in Table 1) who was further described by Brusasco et al. [6, 9] and Spoerri et al. [19]
bElbaum et al. [7] and Hendrix et al. [8] reported two patients with a disease classified as MAUIE syndrome that shared almost all clinical findings with IWC
cAdditional clinical data of patients first described by Diociaiuti et al. [17]
dMonozygotic twin sister of patient 35, with a very similar phenotype
eAffected offsprings of patient 37
fMH is visible on published pictures of Marghescu et al. [3] and Krunic et al. [12]
ga 11 years old female was clinically characterized by Long [18]















Finger length relative to palms may be decreased [19].
Joint contractions of the fingers, caused by marked
hyperkeratosis, worsen mobility of the hands [19].
Tautness of the skin may also involve elbows, shoulders,
hips and knees, thus resulting in a forced limb flexion
and motor impairment with gait abnormality [16–19].
Fig. 1 Major clinical features of ichthyosis with confetti. Severe ichthyosiform erythroderma: massive verrucous hyperkeratosis on the buttocks (a),
knees (b) and feet (c) in the absence of retinoid therapy. Confetti-like spots of healthy skin are visible on the trunk and cheek (d, e: black rings) of
the same patient. Note the presence of mammillae hypoplasia (d, arrowheads). Ear malformations: hypoplasia of the ear helix (e, f), and lobule (e).
Clinical pictures are from a 8-year-old male (a-e) and a 1-year-old female (f)
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Almost all IWC individuals have small height and
weight for age [1, 17, 19], but usually normal neural devel-
opment. However, peripheral hyperreflexia has been
detected by neurologic examination in four patients [15]
and psychomotor retardation has been reported in one
case [17]. Multiple non-melanoma skin cancers (NMSCs)
have been described in three adult IWC patients [15].
The majority of IWC manifestations are present in the
two previously reported cases of MAUIE (micropinnae,
alopecia universalis, congenital ichthyosis and ectropion)
syndrome (Table 1, cases 3 and 4) [7, 8]. These patients
showed congenital ichthyosiform erythroderma at birth,
normal-appearing skin spots, ear deformity (micropinna
or external ear hypoplasia), ectropion, eclabion and nail
Fig. 2 Major and minor clinical features of ichthyosis with confetti. Mammillae hypoplasia (a, arrowheads), palmoplantar hyperkeratosis (b), hypertrichosis
of acral dorsal areas (arrowheads) (c) and back (d), scaling and hyperkeratosis of the scalp (e), large lunulae (f), long nail plates and unguis inflexus (g),
severe eyelid ectropion (h). Clinical pictures are taken from a female at the age of 1 year (b, e, f), 2.5 (c) and 2.7 years (a, d) and a male at the age of 5 (g)
and 8 (h) years. Note the healthy skin confetti-like spots (a, d: black rings) which became evident after hyperkeratosis shedding due to retinoid therapy
Guerra et al. Orphanet Journal of Rare Diseases  (2015) 10:115 Page 6 of 16
thickening [7, 8]. At the time of examination, the two
adult men also presented a complete absence of hair all
over the body [7, 8]. NMSCs were additional findings in
both cases [7, 8]. Although not further characterized, these
patients may be considered suffering from IWC [2, 15].
Spoerri et al. [19] analysed a cohort of 6 unrelated,
genetically characterized, IWC patients and suggested
that clinical features of the disease may be grouped into
major and minor criteria for diagnosis. Major criteria
include all symptoms that the Authors identified as
constantly associated with IWC in their cohort, i.e.
erythroderma since birth, confetti-like spot appearance,
scaling with changing severity, dorsal acral hypertricho-
sis, hypoplasia of mammillae and malformation of ears.
Clinical features which were not always present in every
patient were considered as minor criteria. Based on
literature data (Table 1), palmoplantar keratoderma and
ectropion appear as frequent as the major clinical find-
ings identified by Spoerri et al. [19].
Aetiology
IWC is a disorder of keratins. Keratins are major struc-
tural proteins of epithelial cells. They are obligate
heterodimers of an acidic type I and neutral-basic type II
polypeptide [21, 22]. Keratins have a characteristic
expression patterns in normal human epithelial tissues
according to the function and body site of each cell type.
Some of them can have a very restricted tissue-
specificity [23, 24]. For example, differentiating keratino-
cytes of the epidermis express a particular pair of type I
and type II cytokeratins, keratin 10 (K10) and keratin 1
(K1) [25]. All keratins share a common structure
composed of a central rod domain, through which they
interact to form dimers, flanked by a N- (head) and C-
terminal (tail) domain, which are important for elong-
ation and lateral alignment of K1/K10 heterodimers
[22, 25, 26]. The C-terminal “tail domain” of K1 and
K10 is unusually glycine rich. In addition, the K10 tail
shows extensive size polymorphism due to variable
numbers and sizes of glycine loops [27]. K1/K10
Fig. 3 Schematic of the copy-neutral mechanism of mitotic
recombination leading to revertant mosaicism in a patient affected
with ichthyosis with confetti. The patient is heterozygous for a
pathogenic mutation in the KRT10 locus (17q21.2, indicated by a
horizontal bar within the long arm of the chromosome). During
somatic cell division, the parental affected keratinocyte bears
homologous chromosomes with wild-type (wt) and mutant (mut)
genotypes (a). Following a crossover event proximal to the KRT10
locus both homologous chromosomes will have one chromatid
carrying each genotype (b). Then, daughter cells receiving the same
allele will be homozygous at that locus for either wild-type (revertant
cell) or mutant (affected cell) genotype (c). A single revertant daughter
cell will expand and give rise to the “confetti-like” skin spot
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heterodimers assemble to form the intermediate
filaments (IF) cytoskeleton of differentiating epidermal
keratinocytes [21].
IWC is due to dominant negative mutations in the K10
gene, KRT10, which maps to chromosome 17q21.2 and
consists of 8 exons. The large majority of the 13 KRT10
mutations identified so far represent de novo events. All
the mutations are single nucleotide substitutions or small
insertions and deletions located in exon 6, intron 6 splice
sites and exon 7 (Table 1) [13, 14, 17, 19]. Of note, each
mutation results in a C-terminal frameshift that converts
the glycine/serine-rich K10 tail to an arginine-rich carboxy-
terminal sequence [13]. As arginine-rich motifs are posi-
tively charged and encode nuclear localization sequences
leading to nuclear entry, mutant K10, and its natural
partner K1, accumulates within the nucleus, specifically
within nucleoli, which are site of active synthesis of
ribosomal RNA [13, 15].
Choate et al. [16] have recently described a new IWC
subtype, named IWC-II or IWC-K1, due to a heterozy-
gous de novo single base-pair insertion in the last exon of
K1 gene (KRT1) which maps to chromosome 12q13.13.
Similarly to KRT10 gene defects, the KRT1 mutation
introduces a C-terminal frameshift, which results in the
replacement of the last 22 K1 aminoacids by a novel 30-
aminoacid peptide. In both IWC subtypes the frameshift
peptide is implicated in the dominant negative effect that
disrupts the interactions of K1/K10 tails, leading to the
collapse of IF network and mislocalization of the mutant
proteins to the nucleus [13, 16].
Of note, the KRT10 gene mutations identified in the
germline of IWC patients are not found in the DNA ex-
tracted from the “confetti-like” spots [13, 14]. Spots are not
visible at birth, appear and expand over time, and have nor-
mal tissue architecture. Such observations led Choate et al.
to investigate white spot-purified DNA using high-density
Fig. 4 Histology and immunofluorescence findings in ichthyosis with confetti caused by KRT10 mutation. The epidermis appears acanthotic and
hyperkeratotic with parakeratosis, a reduced granular layer and cytoplasmic vacuolization in suprabasal keratinocytes (a). Higher magnification of
the inset depicted in panel (a) highlighting the perinuclear vacuolization in suprabasal keratinocytes (b). Immunofluorescence labelling for keratin
10 (K10) shows reduced cytoplasmic staining in epidermal suprabasal cell layers, dot-like labelling of numerous nuclei in suprabasal epidermis and
bright perinuclear rings (c). Higher magnification of the inset depicted in panel c showing that nuclear labeling is mainly localised to nucleoli (d).
Haematoxylin-eosin staining (a and b), original magnification × 200 (a). Nuclear DAPI counterstaining (c and d), original magnification × 200 (c)
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single nucleotide polymorphism genotyping platforms [13].
In paired analysis with blood-purified genomic DNA, each
DNA sample from 28 white spots taken from six independ-
ent individuals showed homozygous genotypes of a single
region of chromosome 17q with copy number equals to
two, indicating loss-of-heterozygosity (LOH). The delin-
eated LOH intervals span from a proximal breakpoint to
the telomere and varied among samples. However they
overlapped and identified the proximal boundary of the
KRT10 locus. Thus, white spots represent “repaired” skin
due to independent events of reversion of KRT10mutations
via mitotic recombination (Fig. 3). Since white spots can be
hundreds and expand over time, the recombination event is
expected to occur at a high frequency and to confer select-
ive growth advantage to revertant cell clones. A similar
copy-neutral mechanism of genetic recombination was
discovered in IWC-II. In this subtype the revertant
tissue DNA from several revertant spots harbors
overlapping LOH intervals on chromosome 12 with
breakpoints proximal to the KRT1 locus, indicating
frequent somatic reversion of the KRT1 mutation via
mitotic recombination [16].
Fig. 5 Proposed diagnostic algorithm for ichthyosis with confetti. Medical history and physical examination raise diagnosis suspicion. Histological
examination and keratin immunolocalization show specific findings, such as suprabasal keratinocyte vacuolization and nuclear keratin staining,
respectively. Electron microscopy may further support the diagnosis. Finally, mutational analysis of KRT10/KRT1 genes represents the gold standard
to confirm the diagnosis. Findings relevant to differential diagnosis are in bold
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Diagnosis
IWC diagnosis is based on dermatologic evaluation, and
personal and family history. Skin manifestations, in par-
ticular the presence of verrucous hyperkeratotic plaques
and associated findings such as ear and mammillae hypo-
plasia and hypertrichosis, should be carefully evaluated.
However, IWC clinical suspicion is usually delayed until
the detection of white skin spots. In addition, family history
is rarely informative, as most cases are sporadic. Labora-
tory analyses are mandatory to confirm the diagnosis and
represent the only mean to assess it before the appearance
of healthy skin macules.
At first, biopsy should be taken for histological examin-
ation from affected skin. Histopathologically, the ichthyotic
skin in IWC shows the following alterations of the epider-
mis: hyperkeratosis with focal parakeratosis (retention of
cell nuclei in the stratum corneum), a reduced granular
layer and pronounced perinuclear vacuolization of scat-
tered keratinocytes in the suprabasal epidermal layers
(Fig. 4a, b) [6, 11, 13, 14, 17]. The presence of binucleated
keratinocytes has also been reported [3, 6]. IWC-II skin
shows a thickened stratum corneum without parakeratosis,
milder perinuclear vacuolization with rare binucleated cells
and prominent coarse keratohyalin granules, the latter
Table 2 Differential diagnosis between congenital ichthyosiform erythroderma (CIE) and ichthyosis with confetti (IWC) / congenital
reticular ichthyosiform erythroderma (CRIE)
CIE IWC (CRIE)





Autosomal recessive Autosomal dominant
Mutated genes aABCA12, ALOXE3, ALOX12B, CERS, CYP4F22, NIPAL4,
PNPLA1, TGM1
KRT10, KRT1
Gene function Epidermal lipoxygenase/hepoxilin metabolism,




Onset At birth At birth
Initial clinical
presentation
CIE or, less frequently, collodion baby CIE or collodion baby
Disease course Ranging from mild to severe During childhood numerous spots of normal skin manifest and are the
hallmark of the disease. A later age for normal skin spot appearance
characterizes IWC caused by KRT1 mutation
Distribution of
scaling
Generalized, focally pronounced scaling possible Verrucous adherent hyperkeratosis, more evident on limbs, possible.
Later reticular ichthyosiform pattern
Scaling type/color Fine/white or gray Fine to coarse, yellow-brown
Erythema Variable, often pronounced Pronounced
Palmoplantar
involvement
Mild to pronounced Mild to pronounced
Hypohidrosis Moderate to severe Reported in some cases
Scalp
abnormalities
Scarring alopecia possible Scaling alopecia possible, hair loss and alopecia universalis reported
Other skin
findings
Rarely ectropion Hypertrichosis, ectropion, eclabion
Associated
findings
Failure to thrive, short stature (if severe) Ear deformities, mammillae hypoplasia, growth failure
Risk of death Present during neonatal period Elevated during neonatal period
Histopathology Hyperkeratosis with occasional parakeratosis, normal
or thickened granular layer, pronounced acanthosis
Hyperkeratosis with/without (KRT10/KRT1-subtypes) parakeratosis,
reduced or absent granular layer, pronounced perinuclear vacuolisation
of suprabasal keratinocytes; coarse keratohyalin granules in KRT1-
subtype.
Immunopathology No specific findings Reduction of keratin cytoplasmic staining in epidermal suprabasal cell
layers, dot-like labelling of numerous nuclei in suprabasal epidermis,
bright perinuclear rings in scattered keratinocytes
aABCA12 ATP-binding cassette subfamily A12; ALOX arachidonate lipoxygenase; CERS3 ceramide synthase 3; CYP4F22 cytochrome P450 4 F22; NIPAL4 NIPA-like
domain containing 4; PNPLA1 patatin-like phospholipase domain-containing protein 1; TGM1 transglutaminase-1; KRT10/KRT1 keratin 10/1 [4, 28, 29]
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being absent in the classical IWC form [16]. On the other
hand, a skin biopsy taken within a spot of normal appear-
ing skin always reveals normal architecture. Overall, the
histopathological findings of IWC, and in particular the
presence of keratinocyte vacuolization, are characteristic
and should prompt further diagnostic investigations. Spe-
cifically, immunopathological analysis of K10 and K1
expression in the epidermis should be performed. This is
carried out by immunofluorescence labelling on formalin-
fixed, paraffin-embedded skin sections with commercially
available monoclonal antibodies to K10 and K1.
Immunofluorescence labelling for K10 in IWC shows
a marked reduction of the cytoplasmic staining in
epidermal suprabasal cell layers, collapsed filament net-
works visible as bright perinuclear rings in scattered ker-
atinocytes and a dot-like labelling of numerous nuclei in
suprabasal epidermis (Fig. 4c, d), while in the healthy
control skin K10 is only localized to the keratinocyte
cytoplasm [13, 14, 17]. Similar findings have also been
described for the partner keratin, K1 [13]. Counterstain-
ing with the nucleolar markers fibrillarin shows that K10
and also K1 localize to the nucleolus [13]. Immunofluor-
escence labelling for K1 in the IWC-II subtype reveals
perinuclear rings in affected skin [16]. The nuclear stain-
ing for K10 has been described only in IWC epidermis
and can be considered a diagnostic hallmark. In
addition, K10 immunolabelling performed on archival
skin biopsies can allow retrospective diagnosis [17].
At the ultrastructural level, the most significant findings
in IWC are the presence of binuclear keratinocytes and
cup- or bowl-like perinuclear masses of granular material
in the vacuolized superficial keratinocytes [3, 6, 9, 12]. A
closer examination demonstrates that this material is
composed by thin interlacing filaments [6, 9, 12].
Additional electron microscopy abnormalities include
marked reduction in the total number of keratin tonofila-
ments in cytoplasm, poorly formed desmosomes and
sparse and tapered bundles of keratin filaments attached
to desmosomes [13].
Altogether, histopathological and immunofluorescence
findings of IWC are pathognomonic. Electron microscopy
may further support the diagnosis. Finally, mutational
analysis of KRT10 and KRT1 genes is at present the gold
standard to confirm IWC diagnosis and provides a firm
basis for genetic counseling of affected individuals and
families. Figure 5 summarizes the proposed diagnostic
algorithm for IWC.
Differential diagnosis
IWC at its onset is usually confused with the erythrodermic
form of autosomal recessive congenital ichthyosis (ARCI),
congenital ichthyosiform erythroderma (CIE) [4, 28]. The
following clinical criteria should be used for the differential
diagnosis of IWC: i. the evolution over time of skin
manifestations, in particular a progressive worsening of the
hyperkeratosis may be suggestive of IWC; ii. the type of
scaling and hyperkeratosis, as severe, adherent hyperkera-
totic plaques are not usually seen in CIE; iii. the presence of
additional dermatologic features, in particular ear and
mammillae hypoplasia, and hypertrichosis; iv. the family
history which may point toward a particular mode of inher-
itance and, above all, v. the appearance of confetti-like spots
which drives the correct diagnosis. Histopathological and
immunopathological features also allow to differentiate
IWC from CIE. Indeed, keratinocyte vacuolization and K10
reduced cytoplasmic labeling and nuclear staining are not
found in CIE. Table 2 summarizes differences between CIE
and IWC [4, 29, 30]. IWC can also be differentiated from
syndromic ichthyoses, in particular Netherton syndrome
[31] which manifests at birth with ichthyosiform erythro-
derma, but also presents specific hair alterations (i.e.
trichorrhexis invaginata). The absence of overt skin
blistering in infancy allows to distinguish IWC from other
keratinopathic ichthyoses [4].
Genetic counselling
Genetic counselling in IWC is usually required by the
dermatologist who has in charge the affected patient/
family. It is aimed to: i. confirm the diagnosis, ii. ascer-
tain disease recurrence risk in future pregnancies, and
iii. plan prenatal diagnosis. Histopathological and immu-
nopathological analyses should be considered as first
steps in the diagnostic pathway as they permit to put in
evidence the peculiar tissue architecture and keratin nu-
clear staining of affected skin, thus allowing early diag-
nosis before revertant skin spots become evident [17].
Then, molecular analysis of KRT10 and, if IWC-II
subtype is suspected, of KRT1 gene is aimed at identify-
ing the heterozygous frameshift mutation in the hotspot
genomic region coding for the C-terminal tail of keratins
10 and 1. Mutation identification provides confirmation
of the disease subtype and allows to support the auto-
somal dominant mode of inheritance, which has a 50 %
recurrence risk for subsequent pregnancies of affected
individuals. Knowledge of the mutation also provides a
tool to monitor recurrence risk by prenatal testing.
However, IWC often manifests as a sporadic case, mak-
ing difficult the diagnosis in infancy when “confetti like”
spots are not yet evident and, thus, CIE is usually
suspected. The latter is classically inherited as an auto-
somal recessive trait, which bears a 25 % recurrence risk
for subsequent pregnancies, while sporadic IWC has a
lower risk of recurrence as it results from de novo
event(s) during gametogenesis or at conception. There-
fore, molecular analysis is the only way to properly
counsel the couples in sporadic IWC. Molecular
confirmation after diagnosis by immunofluorescence
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also provides a prenatal diagnostic tool in selected
pregnancies to exclude gonadal mosaicism.
Management including treatment
Due to the rarity of the disease, there are no controlled
studies on IWC management. In general, care of the dis-
ease follows the rules for treatment of ARCI patients.
Like for other congenital ichthyosis forms, the man-
agement of IWC in the neonate, presenting either with
ichthyosiform erythroderma or colloidon baby, requires
admission to a neonatal intensive care unit and a multi-
disciplinary approach, with nursing staff, neonatologists,
dermatologists and other specialists [32]. In particular,
the skin barrier function of the newborn is greatly com-
promised and ongoing water loss can lead to dehydra-
tion and electrolyte imbalance [33]. Moreover defective
barrier allows bacteria and yeast colonization, increasing
risks of infection and sepsis [17]. Thus, neonate care in-
cludes providing a temperature controlled environment
via a humidified incubator, and frequent application of
lubricants such as petrolatum-based products under
sterile conditions [32, 33]. Urinary output, electrolytes
and weight should be monitored and managed with
intravenous hydration, electrolyte repletion and add-
itional nutritional input when necessary. Close monitor-
ing and prompt systemic treatment with antibiotics for
infection is essential.
Therapy of infants, children and adults affected with
ichthyosis, including IWC, is not curative but rather
aimed at symptom relieving. Daily bathing with water
and sodium bicarbonate alkalinizes the epidermis and is
helpful for many patients, especially for mechanical scale
removal. If sodium bicarbonate is not tolerated, rice
starch can be used and is preferred in the first year of
life. During bathing, gentle mechanical keratolysis can
be obtained using sponges or microfiber cloths. Bland
emollients such as petrolatum-based products should be
applied several times a day, especially after bathing, to
prevent drying. Starting from the second year of life,
keratolysis may be obtained through alpha-hydroxy (e.g.
lactic and glycolic) acids and urea or combination of
these ingredients. Alpha-hydroxy acids-based lotions re-
duce corneocyte adhesion and skin thickness and relieve
itching. Urea creams decrease dryness and scaling and
improve skin permeability barrier function by regulating
epidermal gene activity [34]. Of note, topical urea and
alpha-hydroxy acids can also cause skin irritation and
should be applied with caution and only on stubborn
areas in the first three years of life. Moreover, alpha-
hydroxy acids and urea creams may cause systemic
absorption with metabolic acidosis or elevating plasma
urea levels, respectively, when applied over large body
surfaces in infants and toddlers [35, 36]. The use of a
topical retinoid, tazarotene cream, has been reported in
a single IWC patient, specifically on skin areas present-
ing marked hyperkeratosis and around eyes to prevent
ectropion [18]. Although topical tazarotene is increas-
ingly used in ichthyosis patients [37, 38], it can be irritat-
ing [37, 39] and thus not tolerated in erythrodermic
forms of the disease. Its use in IWC should be therefore
cautiously considered for selected skin areas, such as hy-
perkeratotic ones or eyelids, and tolerance evaluated in
each patient. Despite low systemic absorption [40], rules
for pregnancy avoidance during systemic retinoid treat-
ments should also be applied to tazarotene topical therapy.
Due to disease severity, oral retinoids, at first etretinate
[1, 3, 6] and then acitretin [11, 17], have been used in most
IWC patients with positive results, including extension of
the areas of normal confetti-like skin [1, 6, 17]. Systemic
retinoids decrease cell proliferation, thus thinning the
stratum corneum, normalize keratinocyte differentiation,
facilitate desquamation through downregulation of
desmosomal proteins, and have anti-inflammatory proper-
ties [41, 42]. Of note, they have been also shown to down-
regulate K10 expression [41, 43]. However, the lowest
possible dose of a systemic retinoid producing desired
clinical outcomes needs to be titrated. Few IWC patients
require more than 0.5 mg/kg of acitretin once a day
[11, 17]. Importantly, in women of childbearing age
pregnancy must be excluded by negative pregnancy
test (serum levels of human chorionic gonadotropin)
within 2 weeks prior to therapy and effective contra-
ception has to be initiated 4 weeks before, during and
for 3 years after retinoid therapy [44].
Acute adverse effects of systemic retinoids include
skin irritation, fragility and tenderness, mucocutanous
toxicities (in particular cheilitis, epistaxis, eye irrita-
tion), hair loss, and laboratory abnormalities in blood
cell counts, transaminases and serum lipids [44].
Complete blood count, liver function, cholesterol and
lipid levels must be monitored.
Possible long-term retinoid complications include
premature epiphyseal closure, hyperostosis and tendon
calcifications [42, 44]. Although not reported to date
in IWC, they represent an indication to limit the dur-
ation of retinoid therapy or to periodically interrupt
their administration, e.g. during summertime. Baseline
radiographs should also be obtained before program-
ming long-term retinoid therapy. Frequency of X-ray
follow-ups, complemented if required with bone
density scan, will depend on baseline findings and on
clinical manifestations and symptoms. In addition, it
has been hypothesized that retinoids might interfere
with vitamin D metabolism, as their vitamin A-like
biologic activity may hinder vitamin D action [45]. Of
note, vitamin D deficiency has been described in most
types of ichthyoses, in particular severe forms, and
attributed to different factors, such as poor sunlight
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penetration due to hyperkeratotic skin and limited
sun exposure for cosmetic reasons or sun-induced
pain and pruritus [46]. Therefore, it is currently
recommended to screen all congenital ichthyoses for
calcium, phosphorus and vitamin D3 levels and to
provide supplementation if required, in order to treat
vitamin D3 deficiency and prevent possible complica-
tions, such as osteoporosis and rickets. This recom-
mendation should apply also to IWC, although no
data on ions and vitamin D3 levels in these patients
have been reported to date.
For infection control in IWC, topical antiseptics and
antimicrobials must be combined with appropriate sys-
temic therapy. Among other IWC complications, severe
ectropion should be managed by an ophthalmologist to
avoid desiccation, e.g. through regular application of
liquid tears and eye lubricants, and plastic surgery may
be required. Routine otolaryngologist visits are required
to remove desquamated skin from ear canals. Contrac-
tures and gait abnormalities should be evaluated by a
combined team of orthopedists, neurologists and
plastic surgeons and physical therapy should be insti-
tuted for patients with these findings. Psychological
support may be of benefit to both patients and their
families. Regular examination for skin cancer risk is
recommended in adulthood.
Prognosis
IWC, as most other heritable ichthyoses, is a condition
that requires significant attention in the neonatal period.
Although at present there is no curative therapy for all
forms of ichthyoses, including IWC, treatments have im-
proved considerably over the years. Topical medications
can reduce scaling and, thus, patient quality of life. In
addition, retinoid therapies decrease scaling and hyper-
keratosis, and may help in preventing and treating ectro-
pion. Nevertheless, treatments remain symptomatic and
topical ones are time-consuming, challenging patient
and caregiver compliance. Therefore, personalized multi-
disciplinary care plans should be set up and regularly
up-dated by combined dermatologist and patient efforts.
In this context, the support of patient organizations (see
Additional file 1: Table S1) will help affected individuals
and their families to better cope with the disease.
Unresolved questions
There have been recently major advances in our under-
standing of the genetic basis of IWC, with the identifica-
tion of KRT10 and KRT1 mutations. However, several
questions remain unanswered. First, although IWC is con-
sidered a nonsyndromic ichthyosis, it is also true that a
spectrum of ectodermal malformations and neurological
findings leading to different degrees of disability have been
described in affected individuals without any apparent
genotype-phenotype correlation. Indeed, among 40 previ-
ously reported IWC patients, 7 showed both ear deform-
ities and mammillae hypoplasia [17, 19], whereas 6
presented ear deformities [7, 8, 18] or mammillae hypo-
plasia [3, 12, 19] alone (Table 1). Moreover, 4 out of 40
IWC cases were diagnosed with peripheral hyperreflexia
[15] (Table 1). This led some Authors to suggest a
reclassification of IWC as a syndromic ichthyosis [19].
Mutations affecting K10/K1 heterodimers trigger kera-
tinocyte hyperproliferation [24], which explains acanthosis
and hyperkeratosis in IWC patients. Although K10/K1 are
not expressed in nail bed, they are detectable in all other
regions of the nail unit, including eponychium, hypony-
chium and the apical matrix [47, 48]. Therefore KRT10/
KRT1 mutations may also cause nail dystrophies in IWC
patients. In contrast, K10/K1 are absent from the hair
follicle, except for the infundibulum [47], thus raising the
question of pathogenetic mechanisms underlying hypertri-
chosis in IWC. Hypertrichosis is limited to areas of ichthy-
otic skin and Spoerri et al. hypothesized that it may be
due to inflammation and hyperemia, as it happens in post-
cast hypertrichosis [19].
Another open issue is the timing of mitotic recombin-
ation leading to the generation of revertant cells. Spots
become evident as early as 2.5 years of age [17] and can
reach a diameter of 4 cm in adulthood [13]. Since a
white spot represents the expansion of a single homozy-
gotic revertant daughter cell in the absence of pheno-
typic evidence of homozygotic mutant daughter cell
[13], the recombination event should involve the epider-
mal stem cell unit, the specification of which is thought
to occur during embryogenesis [49]. This leads to think
that generation of revertant cells might begin already in
fetal skin. Moreover, as mutant K10 is thought to be in-
volved in triggering the recombination event, KRT10
should be transcriptionally active in the epidermal stem
cell. However, evidence of KRT10 expression in epider-
mal stem cells is still quite limited [50].
A further intriguing question concerns the extremely
high rate of mitotic recombination. As different types of
keratin mutations lead to keratinization diseases without
revertant mosaicism, this implicates the C-terminal frame-
shift peptide of mutant K10 and K1, and its nuclear
localization in the elevated rate of reversion in IWC [15].
Interestingly, revertant spots associated with IWC-II are
lesser in number and smaller in size compared to classic
IWC and harbor clinically apparent affected skin islands
[16]. Moreover, spot-derived keratinocytes of IWC-II give
rise to mixed cultures of revertant and mutant cells, thus
revertant cells seem to have a lesser growth selective ad-
vantage [16]. Finally, nuclear K1 staining is clearly evident
in epithelial cells transfected with mutant K1, but not in
IWC-II patient epidermis [16]. The explanation for these
observations might be dual: i. the sequence of the mutant
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C-terminal frame-shifted K1 peptide harbors very few
positive-charged residues compared to mutant K10 and ii.
only the K10 protein has been linked to cell cycle
control [24, 51, 52], suggesting that mutant K10
might gain and/or loss an activity that interferes with
this process. However, the relationship between IWC
KRT10/KRT1 mutations and the frequency of mitotic
recombination events leading to revertant cells re-
mains to be determined.
Adult individuals with IWC may also have a higher
risk to develop NMSCs [7, 8, 15]. Although such risk
should be carefully re-evaluated by long term patient
follow-up, tumour susceptibility in IWC may have a gen-
etic rationale related to the mechanism of somatic mo-
saicism. Indeed, LOH occurring on chromosome 17q
not only involves the KRT10 locus but can also reduce
to homozygosity mutations and/or variants in epithelial
cancer susceptibility loci distal to the KRT10 allele. For
example, within chromosomal band 17q21.31 several of
these loci have been mapped, including the BRCA1
tumor suppressor [53, 54]. Homozygotic revertant cells
might have a selective growth advantage also as a conse-
quence of LOH events in tumor suppressor loci. How-
ever, available data on BRCA1 mutations and non-
melanoma skin cancer show non-significant association
[54]. In addition, it is not known whether squamous cell
carcinomas reported in IWC individuals developed from
revertant or erythrokeratotic skin. Finally, NMSCs have
been reported also in other ichthyoses, in particular
erythrodermic ones, which do not present revertant
mosaicism [55, 56].
Future perspectives
Revertant skin spots could be exploited in future as a
cell source for a “natural gene therapy” approach in
IWC. The feasibility of ex-vivo gene therapy for genetic
skin disorders has been demonstrated by the successful
engraftment of LAMB3 cDNA retrovirally-corrected epi-
dermal sheets and maintenance of a functional epider-
mis in a 36-year old male with non-Herlitz junctional EB
[57, 58]. However, concerns remain regarding the safety
of this approach as there is an oncogenic potential re-
lated to random insertion of retroviral vectors [59]. By
contrast, the natural occurrence of revertant mosaicism
creates a unique opportunity for therapy in patients, be-
cause the presence of reverted cells circumvents the
need for viral vectors. Persistent ulcers in a patient with
non-Herlitz junctional EB, caused by mutations in the
LAMB3 gene, have been recently treated by transplantation
of punch biopsy specimens taken from one of his revertant
patches with complete re-epithelialization and restoration
of a healthy phenotype and genotype in the grafted areas
[60]. Stable reversion of the EB phenotype by
transplantation of revertant skin in this patient may be
a pioneering work for the development of the “revert-
ant cell therapy” for other genetic diseases with somatic
revertant mosaicism, such as IWC. To date, the only at-
tempt to utilize revertant cell therapy in a clinical set-
ting was performed in an individual with non-Herlitz
junctional EB associated with mutations in COL17A1
who presented revertant skin patches [61]. In this case,
revertant keratinocytes were isolated and expanded into
epidermal sheets that were subsequently grafted back
onto the patient. However fewer than 3 % of the cells
remained corrected in the graft and there was no
clinically relevant outcome.
The persistence of revertant clones in patients with re-
vertant mosaicism indicates that reversion events occur in
epidermal stem cells and that naturally-corrected stem cell
clones may be under strong positive selection [13, 62].
Therefore, efficacy and long-term persistence of the
regenerated epidermis after autotransplantation requires
epidermal stem cell maintenance in cultured sheets and
their grafting onto the patients [63]. We hypothesize that,
with optimized culture conditions, the “revertant cell ther-
apy” might be applied in future to IWC. Nevertheless, in
this scenario, the possibility of homozygosity for muta-
tions in tumor suppressors should be carefully considered
together with the potential therapeutic advantage of
reversion.
Conclusions
IWC is a very rare genodermatosis and represents the most
impressive example of revertant somatic mosaicism. The
IWC phenotype is characterized by a wide spectrum of
clinical features, in addition to erythrodermic ichthyosis.
The recent discoveries in IWC genetics have led to a better
understanding of disease aetiology and made available mo-
lecular diagnostic tools. Disease care requires a multidis-
ciplinary approach, but remains symptomatic. However,
based on current scientific and technological progresses,
new therapeutic strategies potentially able to cure skin
manifestations might be developed in future.
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